Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

EQ vs CRVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRVS Captures Overall Composite Edge (44.4 HOLD vs 48.0 HOLD), While EQ Leads 3–1 on Growth & Valuation Pillars

CRVS Overall Winner 6-Pillar Tally: EQ 3 – 1 CRVS (2 Tie) Matrix Metrics: EQ 3 – 5 CRVS

As of Nov 19, 2026, Corvus Pharmaceuticals, Inc. (CRVS) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (44.4/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.12 (1.5x Forward P/E, 0.0% operating margin) versus CRVS at $10.01 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CRVS 44.4/100 HOLD), CRVS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY).
  • Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile CRVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EQ vs CRVS
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49
CRVS NASDAQ Head-to-Head Winner
Corvus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$10.01
-1.77% 1D
Market Cap $850.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 68% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $10.45 · SMA50: $10.91

6-Pillar Scorecard Institutional Category Breakdown (EQ 3 – 1 CRVS)

Columns: Metric · EQ · CRVS
1. Valuation Multiples EQ
Forward P/E 1.5x N/M
Trailing P/E 1.5x N/M
PEG Ratio N/M N/M
EV / Revenue 7.7x N/M
2. Growth & Scale CRVS
Revenue Growth (YoY) -52.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.4M N/A
Market Cap $90.6M $850.3M
3. Profitability & Quality Tie
Gross Margin 100.0% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.0% -45.9%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$20M -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage $57M Net Cash $14M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 261.3% (100th %ile) 166.2% (25th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EQ (3) vs CRVS (5)
Institutional Metric EQ CRVS Criterion Row Edge
Market Capitalization
Scale
$90.6M $850.3M Larger Scale CRVS
Trailing P/E Ratio
Valuation
1.5x N/M Lower Multiple EQ
Forward P/E Ratio
Valuation
1.5x N/M Lower Multiple EQ
Revenue Growth (YoY)
Growth
-52.3% +0.0% Higher Growth CRVS
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.0% -45.9% Higher ROE CRVS
52-Week Range Position
Momentum
11% ($1–$4) 18% ($6–$27) Stronger Trend CRVS
Beta / 30D Volatility
Risk Regime
1.53β · 93% Vol 1.82β · 68% Vol Lower Realized Risk CRVS
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite EQ
Trailing 12M Revenue (USD)
Operating Scale
$4.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($57M Net Cash) -$48M ($14M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRVS +20.73 pp
EQ: -21.13% · CRVS: -0.4%
3M Horizon CRVS +20.75 pp
EQ: -51.52% · CRVS: -30.77%
6M Horizon CRVS +25.85 pp
EQ: -49.32% · CRVS: -23.47%
1Y Horizon EQ +1.88 pp
EQ: +12.0% · CRVS: +10.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs CRVS. Trailing 12-month operating profitability (EQ 0.0% vs CRVS 0.0%) and valuation multiples (EQ 1.5x vs CRVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x
CRVS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRVS BREAKDOWN
94d in phase · OBV NEUTRAL
Current IV 166.2%
IV Percentile 25th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $850.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EQ vs CRVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Corvus Pharmaceuticals, Inc. (CRVS) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (44.4/100 HOLD vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.12 (1.5x Forward P/E, 0.0% operating margin) versus CRVS at $10.01 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. CRVS 44.4/100 HOLD), CRVS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile CRVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRVS leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with CRVS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EQ generates $4.4M in USD-normalized revenue versus N/A for CRVS. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRVS.

EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin), whereas CRVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus CRVS (-45.9% ROE) capital efficiency.

In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk). By comparison, CRVS carries 166.2% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.